Viewing Study NCT07158957


Ignite Creation Date: 2025-12-24 @ 6:31 PM
Ignite Modification Date: 2025-12-29 @ 10:08 PM
Study NCT ID: NCT07158957
Status: RECRUITING
Last Update Posted: 2025-09-08
First Post: 2025-03-28
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: WOMENinMOTION An Intervention Model for Pelvic Girdle Pain
Sponsor: Vastra Gotaland Region
Organization:

Study Overview

Official Title: WOMENinMOTION An Intervention Model for Pelvic Girdle Pain to Acquire Health-promoting Habits in Pregnancy and Prevent Chronic Pain in Women
Status: RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: WIMPGP
Brief Summary: The overall aim is to educate women to handle common pregnancy-related pain experiences to facilitate healthy life-long physical activity habits and prevent chronic pain.

Our developed WOMENinMOTION model with person-centred preventions and interventions focused on management of pain components added to usual care, will be evaluated in a randomized control study against usual care.

Data and method The model WOMENinMOTION is built on pain education and management of the sensory, emotional, and cognitive components of pain. Through pain management and motivation, pregnant women are guided to choose personal tools for health-promoting physical activity and adaptation of daily activities. Instructive films of exercises, pelvic belt application, and knowledge to meet worries are provided digitally. When the digital content is insufficient, the model is supported by physiotherapist.

Plan for project realisation WOMENinMOTION developed in collaboration with women with PGP, will be pilot tested including analysis of focus groups interviews 2024. The model is evaluated by self-reported questionnaires in a multicenter randomised controlled trial 2025-27 with primary outcomes: physical activity, function and health in gestational week 35, 4 months, 1 and 2 years after birth. Secondary outcomes is PGP prevalence, satisfaction with care, and health economy.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
2022-00146 OTHER_GRANT FORTE View
VGRINN-979977 OTHER_GRANT Västra Götalandsregionens Innovationsfond View
VGRINN-993309 OTHER_GRANT Västra Götalandsregionens Innovationsfond View